Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin in Overweight Insulin-Resistant Type 1 Diabetes
NCT05368402Phase 2Terminated
- Sponsor
- Dompé
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Ladarixin Group with Placebo Group (2 arms). Primary endpoint: Number of Participants With an HbA1c Reduction From Baseline of ≥0.50% Without Episodes of Severe Hypoglycemia at 28 weeks. Started Sep 2022; status: terminated.
02
Drugs
ladarixin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05368402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368402.